{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:51:03Z","timestamp":1790351463039,"version":"4.1.0"},"reference-count":78,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["22-74-10117"],"award-info":[{"award-number":["22-74-10117"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Chronic myeloid leukemia (CML) is an oncological myeloproliferative disorder that accounts for 15 to 20% of all adult leukemia cases. The molecular basis of this disease lies in the formation of a chimeric oncogene BCR\u2013ABL1. The protein product of this gene, p210 BCR\u2013ABL1, exhibits abnormally high constitutive tyrosine kinase activity. Over recent decades, several targeted tyrosine kinase inhibitors (TKIs) directed against BCR\u2013ABL1 have been developed and introduced into clinical practice. These inhibitors suppress BCR\u2013ABL1 activity through various mechanisms. Furthermore, the advent of RNA interference technology has enabled the highly specific inhibition of BCR\u2013ABL1 transcript expression using small interfering RNA (siRNA). This experimental evidence opens avenues for the development of a novel therapeutic strategy for CML, termed siRNA therapy. The review delves into molecular genetic mechanisms underlying the pathogenesis of CML, challenges in CML therapy, potential molecular targets for drug development, and the latest results from the application of siRNAs in in vitro and in vivo CML models.<\/jats:p>","DOI":"10.3390\/biom14060644","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T06:35:32Z","timestamp":1717137332000},"page":"644","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia"],"prefix":"10.3390","volume":"14","author":[{"given":"Vera","family":"Vysochinskaya","sequence":"first","affiliation":[{"name":"Institute of Biomedical Systems and Biotechnology, Peter the Great Saint Petersburg Polytechnic University, 29 Ulitsa Polytechnicheskaya, 194064 St. Petersburg, Russia"},{"name":"Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15\/17 Ulitsa Prof. Popova, 197376 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olesya","family":"Dovbysh","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Systems and Biotechnology, Peter the Great Saint Petersburg Polytechnic University, 29 Ulitsa Polytechnicheskaya, 194064 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Gorshkov","sequence":"additional","affiliation":[{"name":"Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15\/17 Ulitsa Prof. Popova, 197376 St. Petersburg, Russia"},{"name":"Almazov National Research Centre, Akkuratova str. 2, 197341 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Brodskaia","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Systems and Biotechnology, Peter the Great Saint Petersburg Polytechnic University, 29 Ulitsa Polytechnicheskaya, 194064 St. Petersburg, Russia"},{"name":"Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15\/17 Ulitsa Prof. Popova, 197376 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6606-3309","authenticated-orcid":false,"given":"Michael","family":"Dubina","sequence":"additional","affiliation":[{"name":"Russian Academy of Sciences, 14 Leninskiy pr., 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1391-7139","authenticated-orcid":false,"given":"Andrey","family":"Vasin","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Systems and Biotechnology, Peter the Great Saint Petersburg Polytechnic University, 29 Ulitsa Polytechnicheskaya, 194064 St. Petersburg, Russia"},{"name":"Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15\/17 Ulitsa Prof. Popova, 197376 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2012-9461","authenticated-orcid":false,"given":"Yana","family":"Zabrodskaya","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Systems and Biotechnology, Peter the Great Saint Petersburg Polytechnic University, 29 Ulitsa Polytechnicheskaya, 194064 St. Petersburg, Russia"},{"name":"Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15\/17 Ulitsa Prof. Popova, 197376 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"ref_1","first-page":"1497","article-title":"A Minute Chromosome in Human Chronic Granulocytic Leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(77)91415-5","article-title":"15\/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia","volume":"309","author":"Rowley","year":"1977","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","article-title":"A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia","volume":"300","author":"Grosveld","year":"1982","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/306239a0","article-title":"Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia","volume":"306","author":"Heisterkamp","year":"1983","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl Gene of the Philadelphia Chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399403006835","article-title":"Molecular pathogenesis of chronic myeloid leukaemia","volume":"5","author":"Smith","year":"2003","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/ejh.12743","article-title":"Population-based assessment of chronic myeloid leukemia in Sweden: Striking increase in survival and prevalence","volume":"97","author":"Gunnarsson","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/21691401.2017.1307210","article-title":"Advances in siRNA delivery in cancer therapy","volume":"46","author":"Singh","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.apsb.2020.10.005","article-title":"Small interfering RNA for cancer treatment: Overcoming hurdles in delivery","volume":"10","author":"Charbe","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.18632\/oncotarget.26837","article-title":"BCR: A promiscuous fusion partner in hematopoietic disorders","volume":"10","author":"Peiris","year":"2019","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","article-title":"Biology of chronic myelogenous leukemia\u2014signaling pathways of initiation and transformation","volume":"18","author":"Melo","year":"2004","journal-title":"Hematol. Clin. N. Am."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic myeloid leukemia: The paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1128\/MCB.23.13.4663-4672.2003","article-title":"The Bcr kinase downregulates Ras signaling by phosphorylating AF-6 and binding to its PDZ domain","volume":"23","author":"Radziwill","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1389557043487321","article-title":"Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment","volume":"4","author":"Guez","year":"2004","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.1128\/MCB.19.10.6918","article-title":"Bcr-Abl with an SH3 Deletion Retains the Ability to Induce a Myeloproliferative Disease in Mice, yet c-Abl Activated by an SH3 Deletion Induces Only Lymphoid Malignancy","volume":"19","author":"Gross","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1128\/MCB.01454-13","article-title":"The Capable ABL: What is its biological function?","volume":"34","author":"Wang","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11899-018-0474-6","article-title":"Chronic Myeloid Leukemia: Beyond BCR-ABL1","volume":"13","author":"Zhou","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/10428199709051777","article-title":"BCR\/ABL transcripts and leukemia phenotype: An unsolved puzzle","volume":"26","author":"Saglio","year":"1997","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7325","DOI":"10.1158\/0008-5472.CAN-10-0607","article-title":"A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors","volume":"70","author":"Seo","year":"2010","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2017.36","article-title":"Differential signaling networks of Bcr\u2013Abl p210 and p190 kinases in leukemia cells defined by functional proteomics","volume":"31","author":"Reckel","year":"2017","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/0003-4819-138-10-200305200-00010","article-title":"Philadelphia chromosome positive leukemias: From basic mechanisms to molecular therapeutics","volume":"138","author":"Kurzrock","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","article-title":"Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib","volume":"101","author":"Corbin","year":"2003","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lympoblastic leukemia with th","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2217\/pgs.12.103","article-title":"Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: The evolving role of Bcr\u2013Abl mutations and mutational analysis","volume":"13","author":"Soverini","year":"2012","journal-title":"Pharmacogenomics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1158\/1078-0432.CCR-18-0167","article-title":"Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias","volume":"24","author":"Schmitt","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety","volume":"9","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/bloodadvances.2019000268","article-title":"Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia","volume":"4","author":"Chan","year":"2020","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr\u2013Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Mauro","year":"2021","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-021-01662-3","article-title":"Asciminib: First Approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cell.2011.08.046","article-title":"Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis","volume":"147","author":"Grebien","year":"2011","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8836","DOI":"10.1074\/jbc.M115.707901","article-title":"Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface","volume":"291","author":"Wojcik","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.febslet.2004.06.048","article-title":"Suppression of Bcr-Abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic\/antiapoptotic genes and cell proliferation factors (microarray study)","volume":"570","author":"Zhelev","year":"2004","journal-title":"FEBS Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11373-006-9080-z","article-title":"Effects of siRNAs in combination with Gleevec on K-562 cell proliferation and Bcr-Abl expression","volume":"13","author":"Baker","year":"2006","journal-title":"J. Biomed. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1358\/mf.2007.29.6.1119167","article-title":"RNA interference\u2014About the reality to be exploited in cancer therapy","volume":"29","author":"Bakalova","year":"2007","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biochi.2024.01.006","article-title":"Cell-penetrating peptide and cationic liposomes mediated siRNA delivery to arrest growth of chronic myeloid leukemia cells in vitro","volume":"221","author":"Vysochinskaya","year":"2024","journal-title":"Biochimie"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.gt.3302328","article-title":"Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy","volume":"12","author":"Scherr","year":"2005","journal-title":"Gene Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11033-006-9006-x","article-title":"Targeting of gene expression by siRNA in CML primary cells","volume":"34","author":"Merkerova","year":"2007","journal-title":"Mol. Biol. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/154545703322617087","article-title":"Specific killing of Ph+ chronic myeloid leukemia cells by a lentiviral vector-delivered anti-bcr\/Abl small hairpin RNA","volume":"13","author":"Li","year":"2003","journal-title":"Oligonucleotides"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jconrel.2010.04.011","article-title":"Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting bcr\u2013abl fusion gene in Chronic Myeloid Leukemia cells","volume":"145","author":"Arthanari","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2016.11.027","article-title":"siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model","volume":"245","author":"Freire","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/nat.2016.0647","article-title":"Silencing of BCR\/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates","volume":"27","author":"Shinkai","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1089\/scd.2018.0196","article-title":"BCR-AblSilencing by siRNA: A Potent Approach to Sensitize Chronic Myeloid Leukemia Cells to Tyrosine Kinase Inhibitor Therapy","volume":"28","author":"Kc","year":"2019","journal-title":"Stem Cells Dev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/jbm.a.36837","article-title":"Cholesterol grafted cationic lipopolymers: Potential siRNA carriers for selective chronic myeloid leukemia therapy","volume":"108","author":"Remant","year":"2020","journal-title":"J. Biomed. Mater. Res. Part A"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejpb.2018.06.018","article-title":"siRNA\/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo","volume":"130","author":"Aliabadi","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2019.08.018","article-title":"siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers","volume":"310","author":"Kucharski","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3324\/haematol.2009.016063","article-title":"Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib","volume":"95","author":"Koldehoff","year":"2010","journal-title":"Haematologica"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood-2002-06-1685","article-title":"Specific inhibition of bcr-abl gene expression by small interfering RNA","volume":"101","author":"Scherr","year":"2003","journal-title":"Blood"},{"key":"ref_64","first-page":"326","article-title":"WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells","volume":"90","author":"Elmaagacli","year":"2005","journal-title":"Haematologica"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/cgt.2013.31","article-title":"Additive antileukemia effects by GFI1B- and BCR\u2013ABL-specific siRNA in advanced phase chronic myeloid leukemic cells","volume":"20","author":"Koldehoff","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00277-012-1575-2","article-title":"Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K\u2013562 with unmodified or chemically modified siRNAs and induction of apoptosis","volume":"92","author":"Kaymaz","year":"2013","journal-title":"Ann. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","article-title":"Genetic and pharmacologic inhibition of \u03b2-catenin targets imatinib-resistant leukemia stem cells in CML","volume":"10","author":"Heidel","year":"2012","journal-title":"Cell Stem Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"17967","DOI":"10.1073\/pnas.0808303105","article-title":"BCR-ABL-transformed GMP as myeloid leukemic stem cells","volume":"105","author":"Minami","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt\u2013\u03b2-catenin signaling","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/leu.2017.87","article-title":"Combined inhibition of \u03b2-catenin and Bcr\u2013Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo","volume":"31","author":"Zhou","year":"2017","journal-title":"Leukemia"},{"key":"ref_71","first-page":"4934","article-title":"DUXAP10 regulates proliferation and apoptosis of chronic myeloid leukemia via PTEN pathway","volume":"22","author":"Yao","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cbin.10989","article-title":"TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K\/Akt\/mTOR signaling pathway","volume":"42","author":"Li","year":"2018","journal-title":"Cell Biol. Int."},{"key":"ref_73","first-page":"451","article-title":"Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia","volume":"487","author":"Koldehoff","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00277-019-03713-y","article-title":"Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo","volume":"98","author":"Jyotsana","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/sj.leu.2403006","article-title":"Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): Prolongation of survival by the combination of interferon alpha and hydroxyurea","volume":"17","author":"Hehlmann","year":"2003","journal-title":"Leukemia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","article-title":"Treatment-free remission in CML: Who, how, and why?","volume":"2017","author":"Mahon","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/17474086.2020.1717944","article-title":"What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia?","volume":"13","author":"Harrington","year":"2020","journal-title":"Expert Rev. Hematol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/6\/644\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:51:20Z","timestamp":1760107880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/6\/644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":78,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["biom14060644"],"URL":"https:\/\/doi.org\/10.3390\/biom14060644","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}